These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

267 related items for PubMed ID: 20696687

  • 1. A study of HER2 gene amplification and protein expression in gastric cancer.
    Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, Salto-Tellez M.
    J Clin Pathol; 2010 Sep; 63(9):839-42. PubMed ID: 20696687
    [Abstract] [Full Text] [Related]

  • 2. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M.
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [Abstract] [Full Text] [Related]

  • 3. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours.
    Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS.
    J Clin Pathol; 2011 Dec; 64(12):1097-101. PubMed ID: 21896578
    [Abstract] [Full Text] [Related]

  • 4. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S, Igarashi H, Nagura K, Kamo T, Kawane K, Mori H, Ozawa T, Maeda M, Konno K, Hoshino H, Konno H, Ogura H, Shinmura K, Hattori N, Sugimura H.
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [Abstract] [Full Text] [Related]

  • 5. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
    Kammori M, Kurabayashi R, Kashio M, Sakamoto A, Yoshimoto M, Amano S, Kaminishi M, Yamada T, Takubo K.
    Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
    [Abstract] [Full Text] [Related]

  • 6. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
    Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A.
    Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
    [Abstract] [Full Text] [Related]

  • 7. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer.
    Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M, Ochiai A.
    Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035
    [Abstract] [Full Text] [Related]

  • 8. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
    Bilous M, Morey A, Armes J, Cummings M, Francis G.
    Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
    [Abstract] [Full Text] [Related]

  • 9. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, Kim BS, Jang SJ, Kang YK.
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [Abstract] [Full Text] [Related]

  • 10. HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases.
    Cappellesso R, Fassan M, Hanspeter E, Bornschein J, d'Amore ES, Cuorvo LV, Mazzoleni G, Barbareschi M, Pizzi M, Guzzardo V, Malfertheiner P, Micev M, Guido M, Giacomelli L, Tsukanov VV, Zagonel V, Nitti D, Rugge M.
    Hum Pathol; 2015 May; 46(5):665-72. PubMed ID: 25800719
    [Abstract] [Full Text] [Related]

  • 11. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
    Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M.
    Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
    [Abstract] [Full Text] [Related]

  • 12. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ, Janjigian YY, Zaidinski M, Hedvat CV, Hameed MR, Tang LH, Hicks JB, Shah MA, Barbashina V.
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N, Dietze O, Hauser-Kronberger C.
    Anticancer Res; 2004 Nov; 24(4):2401-6. PubMed ID: 15330190
    [Abstract] [Full Text] [Related]

  • 14. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB, Kumarasinghe MP, Armes JE, Bilous M, Cummings MC, Farshid G, Fitzpatrick N, Francis GD, McCloud PI, Raymond W, Morey A.
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [Abstract] [Full Text] [Related]

  • 15. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.
    Zhao J, Wu R, Au A, Marquez A, Yu Y, Shi Z.
    Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of the protein expression and gene amplification of HER2 in gastric cancer].
    Liu JL, Li ZK, Xin FJ, Zhao H, Zhao W, Gao Y, Hu JL, Zhang XX, Zhang MS, Zhang BY, Lu Y.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Sep; 16(9):898-901. PubMed ID: 24062004
    [Abstract] [Full Text] [Related]

  • 17. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
    Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T.
    Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
    [Abstract] [Full Text] [Related]

  • 18. Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas.
    Cho EY, Srivastava A, Park K, Kim J, Lee MH, Do I, Lee J, Kim KM, Sohn TS, Kang WK, Kim S.
    Pathology; 2012 Apr; 44(3):216-20. PubMed ID: 22437741
    [Abstract] [Full Text] [Related]

  • 19. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD, Jones MA, Beadle GF, Stein SR.
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [Abstract] [Full Text] [Related]

  • 20. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
    Akhdar A, Bronsard M, Lemieux R, Geha S.
    Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.